Literature DB >> 12368956

An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation.

R Schots1, I Van Riet, T Ben Othman, F Trullemans, M De Waele, B Van Camp, L Kaufman.   

Abstract

We monitored levels of C-reactive protein (CRP) in 96 consecutive adult allogeneic BMT patients (age 15-50 years) transplanted in our unit. Major transplant-related complications (MTC) occurred in 32% of cases and included: hepatic veno-occlusive disease, pneumonitis, severe endothelial leakage syndrome and >II acute GVHD. Transplant-related mortality (TRM) before day 100 post-BMT was 13.5%. Variables included in a stepwise logistic regression model were: gender, age, disease category, donor type, T cell depletion, TBI, use of growth factors, bacteremia, mean CRP-levels >50 mg/l between days 0 and 5 (CRP day 0-5) and >100 mg/l between days 6 and 10 (CRP day 6-10) post-BMT. Only high CRP-levels (for MTC and TRM) (P < 0.001) and donor-type (for TRM) (P= 0.02) were independent risk factors. The estimated probability for MTC was 73% (CRP day 6-10 >100 mg/l) vs 17% (CRP day 6-10 <100 mg/l). Using the same cut-off levels, the probabilities for TRM were 36.5% vs 1% in the identical sibling donor situation and 88% vs 12.5% in other donor-type transplants. We conclude that the degree of systemic inflammation, as reflected by CRP-levels, during the first 5-10 days after BMT identifies patients at risk of MTC and TRM. Our data may be useful in selecting patients for clinical trials involving pre-emptive anti-inflammatory treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368956     DOI: 10.1038/sj.bmt.1703672

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  17 in total

1.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

Review 4.  Graft-versus-host disease biomarkers: omics and personalized medicine.

Authors:  Sophie Paczesny; Nisha Raiker; Sam Brooks; Christy Mumaw
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

5.  Associations between levels of insulin-like growth factor 1 and sinusoidal obstruction syndrome after allogeneic haematopoietic stem cell transplantation.

Authors:  S Weischendorff; K Kielsen; H Sengeløv; K Jordan; C H Nielsen; A E Pedersen; L P Ryder; A Juul; K G Müller
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

6.  Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.

Authors:  Andrew S Artz; Amittha Wickrema; Shira Dinner; Lucy A Godley; Masha Kocherginsky; Olatoyosi Odenike; Elizabeth S Rich; Wendy Stock; Jodie Ulaszek; Richard A Larson; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

7.  Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies.

Authors:  Massimo Offidani; Laura Corvatta; Lara Malerba; Maria-Novella Piersantelli; Esther Manso; Pietro Leoni
Journal:  Support Care Cancer       Date:  2006-02-15       Impact factor: 3.603

8.  Cardiac effects of chronic graft-versus-host disease after stem cell transplantation.

Authors:  Ali Dogan; Orhan Dogdu; Ibrahim Ozdogru; Mikail Yarlioglues; Nihat Kalay; Mehmet Tugrul Inanc; Idris Ardic; Ahmet Celik; Leylagul Kaynar; Fatih Kurnaz; Namik Kemal Eryol; Mehmet Gungor Kaya
Journal:  Tex Heart Inst J       Date:  2013

Review 9.  Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example.

Authors:  Sophie Paczesny; Christine Duncan; David Jacobsohn; Robert Krance; Kathryn Leung; Paul Carpenter; Catherine Bollard; Jamie Renbarger; Kenneth Cooke
Journal:  Proteomics Clin Appl       Date:  2014-10-30       Impact factor: 3.494

10.  Inflammatory Cytokine Profile in Individuals with Inherited Chromosomally Integrated Human Herpesvirus 6.

Authors:  Daniel P Weschke; Wendy M Leisenring; Richard L Lawler; Terry Stevens-Ayers; Meei-Li Huang; Keith R Jerome; Danielle M Zerr; John A Hansen; Michael Boeckh; Joshua A Hill
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-31       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.